HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.

AbstractBACKGROUND & AIMS:
Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas.
METHODS:
We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras(G12D)/Cre (KC) mice and Kras(G12D)/Trp53(R172H)/Cre (KPC) mice at 4 weeks of age (when pancreatic intraepithelial lesions are histologically evident). Antitumor humoral and cellular responses were analyzed by histology, immunohistochemistry, enzyme-linked immunosorbent assays, flow cytometry, and enzyme-linked immunosorbent spot and cytotoxicity assays. Survival was analyzed by Kaplan-Meier analysis.
RESULTS:
The ENO1 vaccine induced antibody and a cellular response and increased survival times by a median of 138 days in KC mice and 42 days in KPC mice compared with mice given the control vector. On histologic analysis, the vaccine appeared to slow tumor progression. The vaccinated mice had increased serum levels of anti-ENO1 immunoglobulin G, which bound the surface of carcinoma cells and induced complement-dependent cytotoxicity. ENO1 vaccination reduced numbers of myeloid-derived suppressor cells and T-regulatory cells and increased T-helper 1 and 17 responses.
CONCLUSIONS:
In a genetic model of pancreatic carcinoma, vaccination with ENO1 DNA elicits humoral and cellular immune responses against tumors, delays tumor progression, and significantly extends survival. This vaccination strategy might be developed as a neoadjuvant therapy for patients with PDA.
AuthorsPaola Cappello, Simona Rolla, Roberto Chiarle, Moitza Principe, Federica Cavallo, Giovanni Perconti, Salvatore Feo, Mirella Giovarelli, Francesco Novelli
JournalGastroenterology (Gastroenterology) Vol. 144 Issue 5 Pg. 1098-106 (May 2013) ISSN: 1528-0012 [Electronic] United States
PMID23333712 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Vaccines, DNA
  • Eno1 protein, mouse
  • Phosphopyruvate Hydratase
Topics
  • Animals
  • Carcinoma, Pancreatic Ductal (drug therapy, genetics, mortality)
  • Enzyme-Linked Immunosorbent Assay
  • Immunity, Cellular (immunology)
  • Immunohistochemistry
  • Mice
  • Mice, Mutant Strains
  • Neoplasms, Experimental (drug therapy, genetics, mortality)
  • Pancreatic Neoplasms (drug therapy, genetics, mortality)
  • Phosphopyruvate Hydratase (immunology)
  • Survival Rate
  • Vaccination (methods)
  • Vaccines, DNA (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: